UBS Boosts Boston Scientific Price Target to $140 After Strong Q3 Earnings

UBS maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) shares and increased its price target to $140 from $135 after the company's strong Q3 earnings. Boston Scientific reported 21.4% YoY revenue growth and organic sales and earnings per share growth that surpassed UBS and consensus expectations. The company also increased its full-year 2025 outlook, anticipating 20% growth and adjusted EPS of $3.02-$3.04.